MTIF3

Across TCGA pan-cancer cohorts, MTIF3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MTIF3 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MTIF3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MTIF3 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD, LSCC, and HNSC are the cancer types where MTIF3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.877	0.683	.014	8	view →
LSCC	DFS	Median	III,IV	0.463	0.796	.030	2	view →
HNSC	DFS	Quartile	IV	0.669	0.897	.038	1	view →
PDAC	DFS	Median	All	0.660	0.772	.045	1	view →
CCRCC	OS	Quartile	All	0.834	1.000	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MTIF3–LUAD (OS)

Open the LUAD breakdown →